Pangenomic Health Inc.
Simbolis: NARA.CN
CNQ
0.08
CADRinkos kaina šiandien
-0.5178
P/E santykis
0.0003
PEG koeficientas
0.77M
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Pangenomic Health Inc. (NARA-CN) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | |||
---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 0.1 | 1.3 | 0 | ||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.net-receivables | 0 | 0.2 | 0 | 0.1 | ||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.other-current-assets | 0 | 0.2 | 0.3 | 0 | ||||
balance-sheet.row.total-current-assets | 0 | 0.5 | 1.7 | 0.1 | ||||
balance-sheet.row.property-plant-equipment-net | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.intangible-assets | 0 | 0 | 0.8 | 0 | ||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0.8 | 0 | ||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.total-non-current-assets | 0 | 0 | 0.9 | 0 | ||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.total-assets | 0 | 0.5 | 2.6 | 0.1 | ||||
balance-sheet.row.account-payables | 0 | 0.4 | 0.2 | 0 | ||||
balance-sheet.row.short-term-debt | 0 | 0.1 | 0 | 0 | ||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | ||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||
balance-sheet.row.other-current-liab | 0 | 0.2 | 0.2 | 0.1 | ||||
balance-sheet.row.total-non-current-liabilities | 0 | 0.5 | 0 | 0 | ||||
balance-sheet.row.other-liabilities | 0 | -0.5 | 0 | 0 | ||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.total-liab | 0 | 0.7 | 0.3 | 0.1 | ||||
balance-sheet.row.preferred-stock | 0 | 0 | 0.5 | 0 | ||||
balance-sheet.row.common-stock | 0 | 11.2 | 4.6 | 0.2 | ||||
balance-sheet.row.retained-earnings | 0 | -15 | -3 | -0.3 | ||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 3.5 | 0.1 | 0.1 | ||||
balance-sheet.row.other-total-stockholders-equity | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.total-stockholders-equity | 0 | -0.2 | 2.2 | 0 | ||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 0.5 | 2.6 | 0.1 | ||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.total-equity | 0 | -0.2 | 2.2 | 0 | ||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||
Total Investments | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.total-debt | 0 | 0.1 | 0 | 0 | ||||
balance-sheet.row.net-debt | 0 | 0 | -1.3 | 0 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | |||
---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -12 | -2.6 | -0.1 | ||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||
cash-flows.row.deferred-income-tax | 0 | 0 | 1.8 | 0 | ||||
cash-flows.row.stock-based-compensation | 0 | 0.6 | 0.1 | 0 | ||||
cash-flows.row.change-in-working-capital | 0 | 0.2 | -0.3 | 0.1 | ||||
cash-flows.row.account-receivables | 0 | -0.1 | 0 | 0 | ||||
cash-flows.row.inventory | 0 | 0.1 | 0 | 0 | ||||
cash-flows.row.account-payables | 0 | 0.2 | 0.1 | 0 | ||||
cash-flows.row.other-working-capital | 0 | 0 | -0.3 | 0.1 | ||||
cash-flows.row.other-non-cash-items | 0 | 8.4 | 0 | 0 | ||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | ||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||
cash-flows.row.other-investing-activites | 0 | 0 | -0.6 | -0.1 | ||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -0.1 | -0.6 | -0.1 | ||||
cash-flows.row.debt-repayment | 0 | -0.1 | 0 | 0 | ||||
cash-flows.row.common-stock-issued | 0 | 1.3 | 2.5 | 0.1 | ||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||
cash-flows.row.other-financing-activites | 0 | 0.4 | 0.5 | 0 | ||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 1.6 | 3 | 0.2 | ||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||
cash-flows.row.net-change-in-cash | 0 | -1.3 | 1.3 | 0 | ||||
cash-flows.row.cash-at-end-of-period | 0 | 0.1 | 1.3 | 0 | ||||
cash-flows.row.cash-at-beginning-of-period | 0 | 1.3 | 0 | 0 | ||||
cash-flows.row.operating-cash-flow | 0 | -2.8 | -1.1 | 0 | ||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | ||||
cash-flows.row.free-cash-flow | 0 | -2.8 | -1.1 | 0 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | |||
---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.gross-profit | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.research-development | 0 | - | - | - | ||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.operating-expenses | 0 | 3.6 | 0.9 | 0.1 | ||||
income-statement-row.row.cost-and-expenses | 0 | 3.6 | 0.9 | 0.1 | ||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||
income-statement-row.row.total-other-income-expensenet | 0 | -8.4 | -1.8 | 0 | ||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.total-operating-expenses | 0 | -8.4 | -1.8 | 0 | ||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||
income-statement-row.row.operating-income | 0 | -3.6 | -0.9 | -0.1 | ||||
income-statement-row.row.income-before-tax | 0 | -12 | -2.6 | -0.1 | ||||
income-statement-row.row.income-tax-expense | 0 | 8.4 | 0 | 0 | ||||
income-statement-row.row.net-income | 0 | -20.3 | -2.7 | -0.1 |
Dažnai užduodami klausimai
Kas yra Pangenomic Health Inc. (NARA.CN) bendras turtas?
Pangenomic Health Inc. (NARA.CN) bendras turtas yra 504142.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra N/A.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.000.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra -0.016.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.000.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.000.
Kas yra Pangenomic Health Inc. (NARA.CN) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -20347972.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 101771.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 3641827.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 0.000.